Eliminating Cancerous Tumors

Company Information





Lilburn, GA

DeoBioSciences is an early-stage biotech company developing a targeted cancer drug.

This drug, based on a naturally-occurring compound, selectively kills both early- and advanced-stage cancer cells in humans, and potentially, in animals.

Cancer is the second-leading cause of death. In the U.S. alone, nearly 2 million new cancer cases are diagnosed each year.

Cancer in pets is a massive problem, too. 1 in 3 dogs will get cancer. And according to the U.S. National Cancer Institute, approximately 12 million new cancer diagnoses are made in dogs and cats each year.

DeoBioSciences’ drug, DBx-31, may be able to help. This drug kills a broad range of tumors, regardless of tissue type or stage of the disease. It eliminates tumors, rather than just sending them into remission. It also targets cancerous cells, not healthy ones.

With the help of cancer research scientists at Cornell University, DeoBioSciences has developed its drug and is raising capital to continue testing its effects. If the next round of testing is successful, the company believes its drug will have a 90% chance to eliminate four of the deadliest cancer types.

Major biotech and pharma companies have confirmed, in writing, their interest in pursuing in-licensing or partnerships with DeoBioSciences, upon the presentation of more positive data.

Team Background

C.P. Wellstone - Clinical Trial Lead
H.G. Schmidt - Lead Cancer Research Scientist
John Adamson - Co-Founder & CEO
$1.07 million
$26K (2%)
Current Valuation
$15.60 million
Min. Investment
Deal Type
Title III
(For all investors)
Offering Type
Learn more on Netcapital